0001124140false00011241402024-05-082024-05-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  May 8, 2024
 
EXACT SCIENCES CORPORATION
(Exact Name of Registrant as Specified in Charter)
 
Delaware 001-35092 02-0478229
(State or Other Jurisdiction
of Incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
 
5505 Endeavor Lane
Madison, WI  53719
(Address of Principal Executive Offices)(Zip Code)
 
Registrant’s telephone number, including area code:  (608) 284-5700
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange
on which registered
Common Stock, $0.01 par value per shareEXASThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 8.01.                        Other Events.

On May 8, 2024, Exact Sciences Corporation (the “Company”) filed with the Securities and Exchange Commission, a prospectus supplement dated May 8, 2024 (the “Prospectus Supplement”) to the Company's automatic shelf registration statement on Form S-3 (Registration No. 333-272196). The Prospectus Supplement was filed to register the resale from time to time by the selling stockholders referenced in the Prospectus Supplement of up to 5,570,132 shares of the Company’s common stock, par value $0.01 per share.

In connection with the Prospectus Supplement, the Company is filing the opinion of its counsel, K&L Gates LLP, regarding the legality of the securities being registered, which opinion is attached as Exhibit 5.1 to this Current Report on Form 8-K.

Item 9.01.                     Financial Statements and Exhibits.
 
(d) Exhibits.   
Exhibit No. Exhibit Description
   
Opinion of K&L Gates LLP
Consent of K&L Gates LLP (included in Exhibit 5.1)
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
2


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 EXACT SCIENCES CORPORATION
   
Date: May 8, 2024By:/s/ Jeffrey T. Elliott
  Jeffrey T. Elliott
  Executive Vice President and Chief Financial Officer

3
EXHIBIT 5.1
image.jpg

May 8, 2024
Exact Sciences Corporation
5505 Endeavor Lane
Madison, WI 53719
Ladies and Gentlemen:
We have acted as counsel to Exact Sciences Corporation, a Delaware corporation (the “Company”), in connection with the prospectus supplement (the “Prospectus Supplement”) to the Registration Statement on Form S-3ASR filed by the Company with the Securities and Exchange Commission (the “SEC”) on May 25, 2023 (File No. 333-272196) (the “Registration Statement”) under the Securities Act of 1933, as amended (the “Securities Act”), with respect to the resale from time to time by the selling stockholders listed in the Prospectus Supplement under the heading “Selling Stockholders” and any additional selling stockholders who will be identified in one or more future prospectus supplements (the “Selling Stockholders”), as detailed in the Prospectus Supplement, of up to 5,570,132 shares (the “Convertible Note Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”). The Convertible Note Shares offered under the Prospectus Supplement may be issued to the Selling Stockholders from time to time upon the conversion of $553,449,000 aggregate principal amount of 1.75% Convertible Senior Notes due 2031 (the “2031 Notes”) issued to certain investors pursuant to privately negotiated exchange agreements (the “Exchange Agreements”) and pursuant to that certain indenture dated as of January 17, 2018 (the “Base Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by the fifth supplemental indenture dated as of April 17, 2024 (the “Supplemental Indenture” and together with the Base Indenture, the “Indenture”).
This opinion letter is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.
You have requested our opinion as to the matters set forth below in connection with the Prospectus Supplement. For purposes of rendering that opinion, we have examined: (i) the Prospectus Supplement; (ii) the Registration Statement; (iii) the Company’s Sixth Amended and Restated Certificate of Incorporation, as amended; (iv) the Company’s Seventh Amended and Restated By-Laws; (v) the Indenture; (vi) the 2031 Notes (as represented by two global notes deposited with the Depository Trust Company); (vii) the Exchange Agreements; (viii) the corporate actions of the Company’s Board of Directors that provide for the approval of the Exchange Agreements, the issuance of the 2031 Notes and the issuance of the Convertible Note Shares upon conversion of the 2031 Notes (the “Authorizing Resolutions”); and (ix) a certificate of an officer of the Company, dated as of the date hereof. Other than our review of the documents listed in (i) through (ix) above, we have not reviewed any other documents or made any independent investigation for the purpose of rendering this opinion.
For the purposes of this opinion letter, we have assumed that: (i) that each document submitted to us is accurate and complete; (ii) that each such document that is an original is authentic, and each such document that is a specimen or a copy conforms to an authentic original; (iii) the conformity to the original or final versions of the documents submitted to us as copies or drafts and that all signatures on each such document are genuine; (iv) each of the Exchange Agreements and Indenture constitute valid and binding obligations of each party (other than the Company) thereto, enforceable against each such party in accordance with their terms; (v) that you have complied with all state and federal statutes, rules and regulations applicable to you relating to the transactions set forth in the Exchange Agreements; and (vi) the Company is and will be at the time of issuance or resale of the Convertible Note Shares a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware.





Exact Sciences Corporation
May 8, 2024
Page 2
In rendering our opinion below, we have also assumed that: (i) the Company will have sufficient authorized and unissued shares of its Common Stock upon any issuance of Convertible Note Shares, (ii) the Authorizing Resolutions have not been, and will not be, revoked, modified or amended, (iii) the issuance of the Convertible Note Shares will be noted in the Company’s stock ledger; and (iv) none of the Selling Stockholders is, or has been during the past three years, an “interested stockholder” of the Company within the meaning of Subsection 203(b)(5) of the General Corporation Law of the State of Delaware, 8 Del. C. § 101 et seq. (the “DGCL”). We have further assumed the legal capacity of natural persons, and we have assumed that each party to the documents we have examined or relied on has the legal capacity or authority and has satisfied all legal requirements that are applicable to that party to the extent necessary to make such documents enforceable against that party. We have not verified any of those assumptions.
Our opinion set forth below is limited to the DGCL and reported decisions interpreting the DGCL.
Based upon and subject to the foregoing, it is our opinion that the issuance of the Convertible Note Shares has been duly authorized and, when issued and delivered in accordance with the Indenture and the 2031 Notes, the Convertible Note Shares will be validly issued, fully paid and non-assessable.
This opinion is rendered solely in connection with the registration of the shares of Common Stock for resale by the Selling Stockholders under the Registration Statement pursuant to the Prospectus Supplement. This opinion is expressed as of the date hereof, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable laws. American Stock Transfer & Trust Company, LLC, in its capacity as the transfer agent for the Common Stock, may rely on the opinion set forth in this letter.
We hereby consent to the filing of this opinion letter with the SEC as Exhibit 5.1 to the Company’s Current Report on Form 8-K relating to the filing of the Prospectus Supplement, which is incorporated by reference in the Registration Statement. In giving our consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder. This opinion is expressed as of the date hereof, and we disclaim any undertaking to advise of any subsequent changes in the facts stated or assumed herein or any subsequent changes in law.
Very truly yours,
/s/ K&L Gates LLP
K&L Gates LLP

v3.24.1.u1
Cover Page
May 08, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date May 08, 2024
Entity Registrant Name EXACT SCIENCES CORPORATION
Entity Central Index Key 0001124140
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-35092
Entity Tax Identification Number 02-0478229
Entity Address, Address Line One 5505 Endeavor Lane
Entity Address, City or Town Madison
Entity Address, State or Province WI
Entity Address, Postal Zip Code 53719
City Area Code 608
Local Phone Number 284-5700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol EXAS
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more EXACT Sciences Charts.
EXACT Sciences (NASDAQ:EXAS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more EXACT Sciences Charts.